Bevacizumab and ranibizumab for neovascular age-related macular degeneration: a treatment approach based on individual patient needs

• Published in: Canadian journal of ophthalmology Vol. 47; no. 2; pp. 165 - 169
• Main Authors: Bellerive, Claudine, MD, MSc, Cinq-Mars, Benoît, MD, FRCSC, Lalonde, Gilles, MD, FRCSC, Malenfant, Mario, MD, FRCSC, Tourville, Éric, MD, FRCSC, Tardif, Yvon, MD, FRCSC, Giasson, Marcelle, BSc, Hébert, Marc, PhD
• Format: Journal Article
• Language: English
• Published: England Elsevier Inc 01-04-2012
• Subjects: Aged; Aged, 80 and over; Angiogenesis Inhibitors - administration & dosage; Angiogenesis Inhibitors - adverse effects; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Bevacizumab; Female; Humans; Internal Medicine; Intravitreal Injections; Male; Middle Aged; Needs Assessment; Ophthalmology; Ranibizumab; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A - antagonists & inhibitors; Visual Acuity - physiology; Wet Macular Degeneration - drug therapy; Wet Macular Degeneration - physiopathology
• ISSN: 0008-4182; 1715-3360
• DOI: 10.1016/j.jcjo.2012.01.011

Abstract Objective To compare the efficacy of intravitreal bevacizumab and ranibizumab for the treatment of neovascular age-related macular degeneration using an as-needed treatment regimen. Design Retrospective chart review. Participants One hundred and ninety two eyes of 184 patients. Methods Patients received an initial treatment of 3 monthly intravitreal injections of ranibizumab or bevacizumab and retreatment is individually considered for each patient on the basis of optical coherence tomography, angiography, and clinical examination. Results Fifty eyes treated with ranibizumab and 142 eyes treated with bevacizumab were included. The average age of the patients at baseline was 76.9 ± 8 years and 76.4 ± 8 years in the ranibizumab and bevacizumab group respectively. Mean visual acuity improved from 0.69 to 0.55 logMAR at 12 months in the ranibizumab group and from 0.70 to 0.67 logMAR in the bevacizumab group. At 12 months, 92% of eyes treated with ranibizumab had lost fewer than 0.3 logMAR, as compared with 83% in the bevacizumab group. The ranibizumab group received a mean of 4.92 injections, compared to 4.75 injections in the bevacizumab group over 12 months. After the first 3 injections, 20% of patients in the ranibizumab group and 26% in the bevacizumab group never needed another injection. Conclusions An approach based on clinical onset and choroidal neovascularization progression at angiography may provide benefit by reducing the number of intravitreal injections required.